Resources Practice resources Product Information, patient education materials, and other resources. Patient Information Patient information on Multiple Myeloma, Products, and patient resources like financial support and and copay cards. Search for: Recent Content Best Treatment for Newly Diagnosed Multiple Myeloma FDA approves isatuximab in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma Top Headlines and Journal Articles for the Week of March 22, 2021 Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions COVID-19 in a Multiple Myeloma Patient New Target for Multiple Myeloma Optimizing the Use of MRD Testing in Multiple Myeloma Switching Select Older Patients to Low Dose of Lenalidomide and Discontinuing Dex is Safe and Effective Daratumumab Monotherapy Demonstrates Efficacy in R/R Myeloma Myeloma News Powered By: EC Approves New Sarclisa IndicationFour Drugs Upfront Yield ‘Unprecedented’ Response in MyelomaEuropean Commission Approves Second Indication Of Sarclisa® (Isatuximab) For Relapsed Multiple MyelomaStudies Suggest People with Blood Cancers May Not Be Optimally Protected after COVID-19 VaccinationPersonalized Cancer Vaccine Given After Adjuvant Therapy Safe, Shows Early Efficacy in Multiple Tumor TypesMolecular Templates to Prioritize Next-Generation ETB CandidatesSpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple MyelomaFDA Approves Isatuximab-Irfc For Multiple MyelomaFDA Approves Sarclisa® (Isatuximab) in Combination With Carfilzomib And Dexamethasone For Patients With Relapsed or Refractory Multiple MyelomaInternational Myeloma Foundation Says FDA Approval of Bristol Myers Squibb’s and bluebird bio’s CAR T-Cell Immunotherapy Treatment for Multiple Myeloma Is Welcome News for Patients